Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised Phase 2 Trial Assessing REGorafenib Combined With IRInotecan as Second-line Treatment in Patients With Metastatic Gastro-oesophageal Adenocarcinomas

Trial Profile

A Randomised Phase 2 Trial Assessing REGorafenib Combined With IRInotecan as Second-line Treatment in Patients With Metastatic Gastro-oesophageal Adenocarcinomas

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 15 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irinotecan (Primary) ; Regorafenib (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms PRODIGE 58; REGIRI

Most Recent Events

  • 24 Oct 2023 Preliminary Results (n=34) assessing Cell-free DNA analysis in patients with metastatic gastroesophageal adenocarcinoma presented at the 48th European Society for Medical Oncology Congress
  • 21 Jan 2023 Primary endpoint To compare the efficacy of regorafenib combined with irinotecan versus irinotecan alone in terms of overall survival (OS)) has not been met according to results presented at the 2023 Gastrointestinal Cancers Symposium
  • 21 Jan 2023 Results presented at the 2023 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top